• Explore /
  • Poster
  • / Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).

Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).

Abstract Poster

Authors

null

Megan Greally

Memorial Sloan Kettering Cancer Center, New York, NY

Megan Greally , Walid K Chatila , Matthew Margolis , Jaclyn Frances Hechtman , Yaelle Tuvy , Ritika Kundra , Marc Ladanyi , David Paul Kelsen , David H. Ilson , Michael F. Berger , Laura H. Tang , David B. Solit , Nikolaus Schultz , Yelena Yuriy Janjigian , Geoffrey Yuyat Ku

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4056)

DOI

10.1200/JCO.2018.36.15_suppl.4056

Abstract #

4056

Poster Bd #

245

Abstract Disclosures

Similar Posters

First Author: Glenn J. Hanna

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

First Author: Laurent Mhanna

First Author: Mark Chang

First Author: Lorenzo Pilla